Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic exposure at the infection site in periprosthetic joint infections
NL-OMON54617Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2020
- Modality
- Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Open-label trial of vancomycin, flucloxacillin, cefuroxime, clindamycin, trimethoprim + sulfamethoxazole and 1 more in periprosthetic joint infection (PJI) (6 cohorts), sponsored by Erasmus MC. Primary endpoint: PK/PD indices relative to MIC. Started Oct 2020; status: recruiting.
02
Drugs
vancomycinflucloxacillincefuroximeclindamycintrimethoprim + sulfamethoxazole
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NL-OMON54617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54617.